BG
TRIB

Bahl & Gaynor’s Trinity Biotech TRIB Stock Holding History

Bahl & Gaynor’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-142
Closed -$251K – 422
2015
Q4 		$251K Sell
142
-105
-43% -$186K ﹤0.01% 388
2015
Q3 		$423K Buy
247
+33
+15% +$79.7K 0.01% 333
2015
Q2 		$578K Buy
214
+10
+5% +$26K 0.01% 307
2015
Q1 		$588K Buy
204
+134
+191% +$372K 0.01% 281
2014
Q4 		$183K Sell
70
-119
-63% -$308K ﹤0.01% 408
2014
Q3 		$519K Buy
189
+26
+16% +$84.5K 0.01% 279
2014
Q2 		$563K Hold
163
– – 0.01% 264
2014
Q1 		$591K Buy
163
+7
+4% +$27.5K 0.01% 256
2013
Q4 		$587K Buy
156
+13
+9% +$46.8K 0.01% 242
2013
Q3 		$467K Buy
+143
New +$418K 0.01% 254

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Bahl & Gaynor's TRIB Position: Q1 2016 in Review

Bahl & Gaynor sold out of Trinity Biotech (TRIB) in Q1 2016, closing a stake of 142 shares — an estimated $251K sold.

Bahl & Gaynor first reported a position in TRIB in Q3 2013 and held it in 10 quarters. The position peaked at $591K in Q1 2014. 79 funds tracked by Wall St. Rank hold TRIB as of Q1 2016.

  • Bahl & Gaynor reported no remaining Trinity Biotech position as of Q1 2016 after selling out during the quarter.
  • Bahl & Gaynor sold 142 Trinity Biotech shares in Q1 2016, an estimated $251K.
  • Bahl & Gaynor first reported a position in Trinity Biotech in Q3 2013 and held it in 10 quarters.
  • Bahl & Gaynor's Trinity Biotech position peaked at $591K in Q1 2014.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2016.

Based on Bahl & Gaynor's 13F filing for Q1 2016, filed 10 May 2016.